Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) (ENSURE-AF)
A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial Fibrillation
Sponsor: Daiichi Sankyo
A PHASE3 clinical study on Atrial Fibrillation, this trial is completed. The trial is conducted by Daiichi Sankyo and has accumulated 11 data snapshots since 2014. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Mar 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2019 — Apr 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Acquaviva delle Fonti, Italy , Afula, Israel , Allentown, United States , Almería, Spain , Amsterdam, Netherlands , Angers, France , Ashkelon, Israel , Auburn, United States , Bad Berka, Germany and 212 more locations